- Home
- ENB vs ZTS Comparison
ENB vs ZTS Comparison
Compare ENB & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENB
- ZTS
- Stock Information
- Founded
- ENB 1949
- ZTS 1952
- Country
- ENB Canada
- ZTS United States
- Employees
- ENB N/A
- ZTS N/A
- Industry
- ENB Natural Gas Distribution
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- ENB Energy
- ZTS Health Care
- Exchange
- ENB Nasdaq
- ZTS Nasdaq
- Market Cap
- ENB 99.9B
- ZTS 73.2B
- IPO Year
- ENB N/A
- ZTS 2013
- Fundamental
- Price
- ENB $44.15
- ZTS $157.13
- Analyst Decision
- ENB Buy
- ZTS Buy
- Analyst Count
- ENB 1
- ZTS 8
- Target Price
- ENB $67.00
- ZTS $211.50
- AVG Volume (30 Days)
- ENB 3.4M
- ZTS 2.8M
- Earning Date
- ENB 08-01-2025
- ZTS 08-05-2025
- Dividend Yield
- ENB 4.38%
- ZTS 1.27%
- EPS Growth
- ENB 1.87
- ZTS 7.32
- EPS
- ENB 1.88
- ZTS 5.57
- Revenue
- ENB $42,395,380,370.00
- ZTS $9,286,000,000.00
- Revenue This Year
- ENB N/A
- ZTS $3.54
- Revenue Next Year
- ENB $3.62
- ZTS $6.11
- P/E Ratio
- ENB $23.47
- ZTS $28.18
- Revenue Growth
- ENB 43.00
- ZTS 6.32
- 52 Week Low
- ENB $35.10
- ZTS $139.70
- 52 Week High
- ENB $47.44
- ZTS $200.33
- Technical
- Relative Strength Index (RSI)
- ENB 38.23
- ZTS 42.87
- Support Level
- ENB $44.13
- ZTS $152.75
- Resistance Level
- ENB $45.36
- ZTS $160.95
- Average True Range (ATR)
- ENB 0.74
- ZTS 3.21
- MACD
- ENB -0.12
- ZTS -0.28
- Stochastic Oscillator
- ENB 6.45
- ZTS 31.24
About ENB Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the us and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. The firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.